iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
iBio, Inc. (IBIO)
NASDAQ:AMEX Investor Relations:
ir.ibioinc.com
Company Research
Source: GlobeNewswire
SAN DIEGO, Sept. 20, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, today announced its financial results for the fiscal year ended June 30, 2024, and provided a corporate update. “Our fiscal year 2024 was a transformational year for iBio, as we’ve solidified our business and financial position as a next-generation antibody company with a machine-learning-enabled platform for designing and developing difficult-to-drug therapeutics,” said CEO and Chief Scientific Officer Martin Brenner, Ph.D., DVM. “We made significant progress entering the fast-growing cardiometabolic and obesity space with our collaboration with AstralBio and strengthened our financial position by eliminating our debt associated with the facility and closing a fully subscribed financing including participation from Ikarian Capital, Lynx1 Capital Management, ADAR1 Capital Management, and other institutional and accredited investors. We continued to bu
Show less
Read more
Impact Snapshot
Event Time:
IBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBIO alerts
High impacting iBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBIO
News
- iBio to Participate in Upcoming Investor ConferencesGlobeNewswire
- iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business DevelopmentGlobeNewswire
- iBio, Inc. (NYSE: IBIO) is now covered by analysts at Brookline Capital Management. They set a "buy" rating and a $3.60 price target on the stock.MarketBeat
IBIO
Sec Filings
- 9/24/24 - Form 10-K/A
- 9/20/24 - Form 10-K
- 9/20/24 - Form 8-K
- IBIO's page on the SEC website